2024-04-11 16:43:08 ET
Summary
- Life science tool companies have faced challenges in the post-pandemic adjustment process, but Bruker has fared better than many due to its leverage to research tools.
- Bruker's high exposure to potentially weaker academic and government end-markets presents challenges, but Bruker's tools address high-priority research areas in biology, pharmaceuticals, and semiconductors.
- Bruker is well-positioned for healthy revenue growth in 2024, with potential growth in the Chinese market and increasing interest in proteomics and spatial biology driving growth opportunities.
- Improving tool functionality and a growing ecosystem of complementary products could drive proteomics and spatial biology to a tipping point where Bruker's revenue really accelerates.
- Bruker is not conventionally cheap but offers growth at a reasonable price for investors who see upside in proteomics and spatial biology research activity/spending.
The post-pandemic adjustment process has been a challenging one for many life science tool companies, as the bio-pharma end-market in particular pulled back significantly on capex in 2023 after overspending budgets during the pandemic to expand capacity for diagnostics, pharmaceuticals, and vaccines....
Read the full article on Seeking Alpha
For further details see:
Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research